Vaso (VASO) ROCE % : -10.54% (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Vaso ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vaso's annualized ROCE % for the quarter that ended in Mar. 2024 was -10.54%.

Vaso ROCE % Historical Data

The historical data trend for Vaso's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaso ROCE % Chart

Vaso Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

3.96

5.28

32.78

21.45

11.54

Vaso Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															3.30	19.01	11.26	10.40	-10.54

Vaso ROCE % Calculation

Vaso's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	4.955	/	( ( (71.645 - 31.506)	+	(75.757 - 30.04) )	/ 2 )
	=	4.955	/	( (40.139	+	45.717)	/ 2 )
	=	4.955	/	42.928
	=	11.54 %

Vaso's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-4.632	/	( ( (75.757 - 30.04)	+	(69.444 - 27.275) )	/ 2 )
	=	-4.632	/	( ( 45.717	+	42.169 )	/ 2 )
	=	-4.632	/	43.943
	=	-10.54 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Vaso (OTCPK:VASO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vaso ROCE % Related Terms

Thank you for viewing the detailed overview of Vaso's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaso (VASO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Vaso Corporation (OTCPK:VASO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

137 Commercial Street, Unit 200, Plainview, NY, USA, 11803

Website

https://www.vasocorporation.com

Vaso Corporation is a medical technology company. It provides diverse product and service categories, including noninvasive monitoring and therapeutic devices, diagnostic imaging equipment, and information technology for enterprises and clinical customers. The company currently operates in three distinct business units namely IT; Professional sales and Equipment. It generates maximum revenue from the IT segment. IT segment focuses on healthcare IT and managed network technology services.

Executives

Leon Dembo	director	137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Janey Moen	director	137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Jun Ma	director	C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Edgar Rios	director	1650 TYSONS BOULEVARD, SUITE 900, MCLEAN VA 22102
Michael Beecher	officer: Chief Financial Officer	C/O DIRECT INSITE CORP, 80 ORVILLE DRIVE, BOHEMIA NY 11716
Joshua Markowitz	director	3131 PRINCETON PIKE, BLDG. 3D, SUITE 200, LAWRENCEVILLE NJ 08648
Jonathan P Newton	officer: Vice Pres Finance & Controller	152 RICHMOND AVENUE, AMITYVILLE NY 11701
Peter C Castle	director	C/O NETWOLVES CORP, 4002 EISENHOWER BLVD, TEMPA FL 33634
David H Lieberman	director	3061 INDUSTRY DR, LANCASTER PA 17603
Behnam Movaseghi	director	C/O KERNS MANUFACTURING CORPORATION, 37-14 29TH STREET, LONG ISLAND CITY NY 11101
Nelson Randall Hill	officer: Senior Vice President	3880 EAST COUNTY HIGHWAY 30A, UNIT 201, SANTA ROSA BEACH FL 24159
William Edward Dempsey	director	52 PARK AVENUE, SANDYMOUNT L2 DUBLIN 4
David Tarachand Singh	officer: Chief Financial Officer	C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Joseph Giacalone	director
Derek Enlander	director	88C UNION AVENUE, CENTER MORICHES NY 11934